Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct-Dec;33(4):333-334.
doi: 10.4103/iju.IJU_250_17.

A game changing LATITUDE: Role of abiraterone plus prednisone in metastatic hormonesensitive prostate cancer. [corrected]

Aditya Prakash Sharma  1
Affiliations

A game changing LATITUDE: Role of abiraterone plus prednisone in metastatic hormonesensitive prostate cancer. [corrected]

Aditya Prakash Sharma. Indian J Urol. 2017 Oct-Dec.

Erratum in

No abstract available

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

References

    1. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352–60. - PubMed
    1. Gandaglia G, Fossati N, Suardi N, Montorsi F, Briganti A. STAMPEDE trial and patients with non-metastatic prostate cancer. Lancet. 2016;388:234–5. - PubMed
    1. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737–46. - PMC - PubMed
    1. James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377:338–51. - PMC - PubMed
    1. Li Z, Bishop AC, Alyamani M, Garcia JA, Dreicer R, Bunch D, et al. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature. 2015;523:347–51. - PMC - PubMed